American Journal of Advanced Drug Delivery Open Access

  • ISSN: 2321-547X
  • Journal h-index: 22
  • Journal CiteScore: 9.36
  • Journal Impact Factor: 5.76
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Abstract

Development and Optimization of RP-HPLC Method for analysis of 5-FU in Human and Rabbit Plasma Samples: Identification and Quantification

Aisha Sethi*, Mahmood Ahmad, Imitaz Ahmad and Sabra Sultana

In vitro and in vivo experiments revealed that drug loaded cross linked chitosan nanoparticles showed; a sustained release profile of 5-fluorouracil compared to the oral solution of 5-FU due to which Area Under Curve (AUC) was increased two times more folds, as promising site specific targeted site of 5-FU to the colon. A simple, accurate, precise, cost effective and sensitive Reversed Phase HPLC (RP-HPLC) method has been developed and validated then, for determination of 5-FU in human and rabbit plasmas. The current RP-HPLC chromatography system is an isocratic of Agilent technologies series 1200 consisted of a pump and variables. Data processing software chem station used with a Wave Length Detector (WLD) for assay of prepared plasma samples. Mobile phase composition was i.e. acetonitrile: water (10:90) at pH 6 and 1.0 mL/min flow rate for 3-4 minutes (retention time). 5-Fluorouracil was detected using a Waters 2996 photodiode array detector at a 260 nm wavelength. The calibration curve was linear over the concentration range of 2-100 ng/ml. This method was specific and co-relation coefficient (r2) is less than or equal to 0.998. It is concluded that reproducible method may be employed for the analysis of 5-Fluorouracil (5-FU) is a broad spectrum anticancer and it is widely used in the treatment of various types of solid cancers. But due to its narrow therapeutic window, plasma concentration is very essential to determine at clinical setups, pharmacokinetic parameters, in rabbit and human plasma samples as well as nanoparticles formulations.

Published Date: 2022-10-17; Received Date: 2022-03-16